CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 718 enrolled
Drug / intervention
PG324 Ophthalmic Solution 0.02%/0.005% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02558400
NCT02558400Phase 3Completed
CompareCT.gov

A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure

Aerie Pharmaceuticals·interventional·Posted Sep 24, 2015·Updated Jun 4, 2019

In Brief

A Phase 3 clinical trial evaluating PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, and 1 other intervention for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 718 participants across 1 site.

Detailed Summary

To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution. Following completion of the Month 12 study visit procedures, subjects will be offered the opportunity to participate in a 2-month observational (i.e., non-interventional) trial extension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 24, 2015
Enrollment StartSep 18, 2015
Primary CompletionMay 17, 2017
Study CompletionJun 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.8 years ago

Interventions

PG324 Ophthalmic Solution 0.02%/0.005%drug

1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Netarsudil (AR-13324) Ophthalmic Solution 0.02%drug

1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Latanoprost Ophthalmic Solution 0.005%drug

1 drop once daily (QD), in the evening (PM) in both eyes (OU)